Akari Therapeutics (AKTX) Notes Payables (2012 - 2026)

Akari Therapeutics (AKTX) has reported Notes Payables for 5 consecutive years, with $49000.0 the latest figure, recorded in Q1 2026.

• Quarterly Notes Payables fell 78.51% year-over-year to $49000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49000.0 (down 78.51% YoY) and the FY2025 annual result came in at $81000.0, down 87.71% from the prior year.
• Notes Payables slipped to $49000.0 in Q1 2026 per AKTX's latest filing, from $81000.0 in the prior quarter.
• Over the last five years, Notes Payables for AKTX reached as high as $659000.0 in Q4 2024 and fell as low as $49000.0 in Q1 2026.
• A 3-year average of $232333.3 and a median of $188500.0 in 2025 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2025 — Notes Payables plunged 87.71% — and 2026, when it sank 78.51%.
• Year by year, Notes Payables stood at $659000.0 in 2024, then tumbled by 87.71% to $81000.0 in 2025, then sank by 39.51% to $49000.0 in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $49000.0, $81000.0, and $198000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.